Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. (ALLO): 12 pipeline candidates · 1 upcoming catalyst · ~62 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
61.6 months
D/E 0.42 · 0% dilution
Lead: Phase 3
12 candidates
1 upcoming, next in ~6179d
0 buys · 12 sells (180d)
A transparent, data-derived signal for Allogene Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$676.5M
Cash
$40.6M
Quarterly Burn
$12.9M
Runway
61.6 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| ALLO-316 | Phase 2 |
| ALLO-329 | Phase 1 |
| ALLO-501 | Phase 2 |
| ALLO-501A | Phase 2 |
| ALLO-647 | Phase 2 |
| allo-715 | Phase 2 |
| cema-cel | Phase 2 |
| cemacabtagene ansegedleucel | Phase 2 |
| cemacabtagene ansegedleucel (cema-cel) | Phase 3 |
| Cyclophophamide | Phase 2 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
206
Total value held
$360.1M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 19,091,095 | $46.6M |
| vanguard capital management llc | 13,842,700 | $33.8M |
| state street corp | 8,660,306 | $21.1M |
| primecap management co/ca/ | 8,379,840 | $20.4M |
| woodline partners lp | 7,002,156 | $17.1M |
| citadel advisors llc | 6,887,120 | $16.8M |
| two sigma investments, lp | 5,375,456 | $13.1M |
| geode capital management, llc | 4,124,178 | $10.1M |
| frazier life sciences management, l.p. | 3,796,668 | $9.3M |
| patient square capital lp | 3,450,000 | $8.4M |
Showing top 10 of 206 institutional holders of Allogene Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Allogene Therapeutics, Inc.'s pipeline?
Allogene Therapeutics, Inc. (ALLO) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Allogene Therapeutics, Inc.'s lead drug candidate?
Allogene Therapeutics, Inc.'s most advanced tracked candidate is ALLO-316 (Phase 2) for Advanced/Metastatic Clear Cell Renal Cell Carcinoma.
What is Allogene Therapeutics, Inc.'s next catalyst?
Allogene Therapeutics, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: OGSIVEO" — expected May 19, 2043.
What is Allogene Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Allogene Therapeutics, Inc. has approximately 61.6 months of cash runway.
What is Allogene Therapeutics, Inc.'s market capitalization?
Allogene Therapeutics, Inc.'s market capitalization is approximately $676.5M.
Get the full picture on Allogene Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.